

National Imaging Associates, Inc. *	
Clinical guidelines: HIP ARTHROPLASTY	Original Date: November 2015
CPT Codes**: <ul style="list-style-type: none"> - Total Hip Arthroplasty (THA): 27130, S2118 - Revision/Conversion Hip Arthroplasty: 27132, 27134, 27137, 27138 <i>**See UM Matrix for allowable billed groupings and additional covered codes</i>	Last Revised Date: May June 2021 <u>2021</u>
Guideline Number: NIA_CG_313	Implementation Date: January <u>2023</u>

General Requirements

Elective hip arthroplasty may be considered if the following general criteria are met:

- Hip pain with documented loss of function, which may include painful weight bearing painful or inadequate range of motion to accomplish age-appropriate activities of daily living (ADLs) and/or employment; and mechanical catching, locking
- ~~Individual Patient~~ is medically stable and optimized for surgery with no uncontrolled comorbidities (such as diabetes)
- ~~Individual Patient~~ does not have an active local or systemic infection
- ~~Individual Patient~~ does not have active, untreated drug dependency (including but not limited to narcotics, opioids, muscle relaxants) unless engaged in treatment program
- ~~Individual Patient~~ has good oral hygiene and does not have major dental work scheduled or anticipated (ideally, within one year of joint replacement), due to increased post-surgical infection risk
- ~~Efforts have been made to ensure that the patient is optimally informed and prepared for surgery~~

Clinical notes should address:

- Symptom onset, duration, and severity

* National Imaging Associates, Inc. (NIA) is a subsidiary of Magellan Healthcare, Inc.

- Loss of function and/or limitations
- Type and duration of non-operative management modalities
- Discussion with patient regarding decision making and timing

Non-operative management must include at least **two** or more of the following unless otherwise specified in clinical indications below:

- Rest or activity modifications/limitations
- Weight reduction for individual patient with elevated BMI
- Protected weight-bearing with cane, walker, or crutches
- Physical therapy modalities
- Physician-supervised exercise program (including home exercise program)
- Pharmacologic treatment: oral/topical NSAIDs, acetaminophen, or analgesics
- Intra-articular injection(s)

INDICATIONS

TOTAL HIP ARTHROPLASTY (THA)

THA may be considered medically necessary when the following criteria are met:

- Hip pathology is due to rheumatoid arthritis ~~(Hochberg, 2012; Jain, 2012)~~,^{1, 2} femoral neck fracture ~~(Kim, 2013; Murphy, 2013)~~,^{3, 4} malignancy, dysplasia, avascular necrosis (confirmed by imaging)⁵ ~~(Moya-Angeler, 2015)~~ or radiographs (X-rays) demonstrate bone-on-bone articulation

AND

- There is persistent pain and documented loss of function with any of the above.

NOTE: There is no medical necessity to perform THA in individual patients with severe radiological disease and no symptoms, except in the case of malignancy

OR

- When **ALL** of the following criteria are met:
 - Pain due to advanced osteoarthritis (Tönnis Grade-2 or 3 [see grading appendix] **AND** documented loss of function that has been present for at least 12 weeks3 months^{6, 7} ~~(Gossec, 2011a, 2011b)~~
 - Failure of **at least 12 weeks3 months** of non-operative treatment, including **at least two** of the following:
 - Rest or activity modifications/limitations⁸ ~~(AAOS, 2017)~~
 - Weight reduction for individual patient with elevated BMI⁸ ~~(AAOS, 2017)~~
 - Protected weight-bearing with cane, walker, or crutches
 - Physical therapy modalities⁹ ~~(Abbott, 2013)~~

- Physician-supervised exercise program (including home exercise program)¹⁰ ([Juhakoski, 2011](#))
- Pharmacologic treatment: oral/topical NSAIDS, acetaminophen, or analgesics⁸ ([AAOS, 2017](#))
- Intra-articular corticosteroid injection⁸ ([AAOS, 2017](#))
- Physical exam demonstrates findings of hip pathology as evidenced by **one or more** of the following:
 - Painful, limited range of motion or antalgic gait
 - Contracture
 - Crepitus
 - Leg length difference
- Radiographic findings show evidence of advanced arthritic changes, described as Tönnis grade 2 or 3 [see grading appendix] or described as X-rays showing advanced changes such as, severe narrowing or bone-on-bone compartment collapse, subchondral sclerosis or cysts, osteophyte formation and/or bony deformity etc.; X-rays described only as showing “severe”, “advanced” or “end-stage” arthritis require more definitive descriptions as stated above. Weightbearing X-rays are not required ([Bessa, 2020](#)).¹¹

NOTE: MRI should not be the primary radiographic test used to determine the presence or severity of arthritic changes in the joint.

- No corticosteroid injection into the joint within 12 weeks of surgery¹²⁻¹⁴ ([Forlenza, 2021; Schairer, 2016; Werner, 2016](#)).



Additional Information

- ~~All requests for THA are to have documentation in the medical record pertaining to the potential risks, benefits, and potential complications specific to this procedure.~~
- All requests for simultaneous bilateral total hip replacements should clearly indicate why simultaneous THA is preferable to staged procedures. Associated risks with simultaneous bilateral total hip replacements should also be discussed with the individual patient and documented in the medical record.

Absolute Contraindications

- Active infection (local or remote). If a local or remote infection is documented in the patient’s history, records should clearly demonstrate that the previous infection had been treated and symptoms have resolved or that the individual patient has no clinical signs or symptoms of the previous infection at the time of the operation.
- ~~Any corticosteroid injection into the joint within 12 weeks of surgery¹²⁻¹⁴ ([Forlenza, 2021; Schairer, 2016; Werner, 2016](#))~~

Relative Contraindications

- Prior infection at site (unless aspiration with cultures and serology [CBC with differential, ESR, CRP] demonstrates no infection). If prior infection at site, tissue biopsies should be sent intra-operatively to exclude latent/dormant infection
- Documented allergy to any proposed component
- BMI > 40¹⁵ ~~(D'Apuzzo, 2014)~~; without attempts at weight loss or discussion of increased risk conferred by BMI
- Compromised soft tissue envelope
- Uncontrolled comorbidities¹⁶ ~~(Clement, 2013)~~

HIP RESURFACING ARTHROPLASTY

Hip resurfacing procedures will be reviewed on a case-by-case basis.

Hip resurfacing arthroplasty may be considered medically necessary when **ALL** of the following criteria are met:

- Pain and documented loss of function are present for at least ~~12 weeks~~ **3 months**
- ~~12 weeks~~ **3 months** of non-operative treatment have failed to improve symptoms
- Physical exam has typical findings of hip pathology as evidenced by **one or more** of the following:
 - Painful, limited range of motion or antalgic gait
 - Contracture
 - Crepitus
 - Leg length difference
- Imaging demonstrates advanced hip joint pathology of at least Tönnis grade 2 or 3, or avascular necrosis involving less than 50% of the femoral head [see grading appendix];
- Male patient is less than 65 years old or female patient is less than 55 years old¹⁷ ~~(Sershon, 2016)~~;
- BMI < 40¹⁸ ~~(Nunley, 2008)~~;
- No corticosteroid injection into the joint within 12 weeks of surgery¹²⁻¹⁴ ~~(Forlenza, 2021; Schairer, 2016; Werner, 2016)~~;

Absolute Contraindications

- Any corticosteroid injection into the joint within 12 weeks of surgery¹²⁻¹⁴ ~~(Forlenza, 2021; Schairer, 2016; Werner, 2016)~~
- Osteoporosis or osteopenia (DEXA scan bone mineral density evaluation)¹⁷ ~~(Sershon, 2016)~~
 - Osteoporosis or poor bone quality may increase the risk of fixation failure or femoral neck fracture after hip resurfacing¹⁸ ~~(Nunley, 2009)~~

- Other co-morbidity (including medications that contribute to decreased bone mineral density (glucocorticoid steroids, heparin, aromatase inhibitors, thiazolidinediones, proton pump inhibitors, loop diuretics, cyclosporine, anti-retrovirals, anti-psychotics, anti-seizures, certain breast cancer drugs, certain prostate cancer drugs, depo-provera, aluminum-containing antacids) that may contribute to active bone demineralization¹⁹ ([Clough, 2021](#))
- Cystic degeneration at the junction of the femoral head and neck on radiographs or MRI or CT
- Malignancy at the proximal femur
- Evidence of current, ongoing, or inadequately treated hip infection, or sepsis
- Female of child-bearing age (due to metal ions circulating in blood with potential risk to fetus)^{20, 21} ([Matharu, 2017; USFDA, 2018](#))
- Chronic renal insufficiency (due to metal ions circulating and potential renal toxicity)²¹ ([USFDA, 2018](#))
- Metal allergy²¹ ([USFDA, 2018](#))

TOTAL HIP ARTHROPLASTY REVISION / CONVERSION ARTHROPLASTY

Hip ~~r~~Revision/~~c~~Conversion ~~a~~Arthroplasty may be considered medically necessary when a previous hip reconstruction meets **ALL** the following criteria in either of the following subsections:

- Previous removal of infected hip prosthesis **AND** no evidence of current, ongoing, or inadequately treated hip infection (ruled out by normal inflammatory markers* (ESR and CRP) or significant improvement in these markers and a clear statement by the treating surgeon that infection has been adequately treated) **AND** off antibiotics²²⁻²⁴ ([Della Valle, 2010; Lee, 2015; Ting, 2017](#)).

***NOTE:** If these inflammatory markers are elevated, further evaluation is required, including an aspiration with synovial fluid WBC count, gram stain and cultures, or an intraoperative frozen biopsy;

OR

- When **ALL** the following criteria are met:
 - Failed hip arthroplasty as defined by symptomatic or unstable joint upon physical exam (documented persistent, severe, and disabling pain, loss of function, instability) or failed previous hip fracture surgery
 - Physical exam and radiographic evidence support extensive disease or damage due to fracture, malignancy, osteolysis, other bone or soft-tissue reactive or destructive process, inappropriate positioning of components, recurrent instability, subluxation, dislocation, critical polyethylene wear, or other mechanical failure. (**NOTE:** MRI is used less often in these circumstances unless it is a metal-on-metal prosthesis and looking for soft-tissue lesions; x-ray, CT, nuclear studies are used more frequently)

- For implant loosening seen on routine X-rays or bone scan, documentation of no current, ongoing, or inadequately treated hip infection, ruled out by normal inflammatory markers (ESR and CRP)^{22, 23, 25-28} (~~Della Valle, 2010; Lee, 2015; Parvizi, 2010, 2013 and 2018; Ting, 2017~~).
- If the revision is for obvious hardware failure only, inflammatory markers are not required.
- No corticosteroid injection into the joint within 12 weeks of surgery¹²⁻¹⁴ (~~Forlenza, 2021; Schairer, 2016; Werner, 2016~~).

Additional Information

- Removal of infected hip prosthesis and subsequent insertion of antibiotic spacer is not considered to be a revision arthroplasty
- All requests for revision THA are to have documentation in the medical record pertaining to the potential risks, benefits, and potential complications specific to this procedure.

GRADING APPENDIX

Tönnis Classification of Osteoarthritis by Radiographic Changes

Grade	Description
0	No signs of osteoarthritis
1	Mild: Increased sclerosis, slight narrowing of the joint space, no or slight loss of head sphericity
2	Moderate: Small cysts, moderate narrowing of the joint space, moderate loss of head sphericity
3	Severe: Large cysts, severe narrowing or obliteration of the joint space, severe deformity of the head

BACKGROUND

HIP ARTHROPLASTY - Total & Revision/Conversion Hip Replacement

This guideline addresses elective, non-emergent hip arthroplasty (hip replacement) procedures, including total hip arthroplasty, resurfacing arthroplasty, and revision/conversion arthroplasty procedures.

Arthritis is the most common cause of chronic hip pain and disability. Degenerative, age-related osteoarthritis causes cartilage to wear away and eventually the bones within the joint rub against each other causing pain and stiffness. In a total hip replacement, the femoral head and acetabulum are removed and replaced with prosthetic components. In hip resurfacing arthroplasty, a metal cup is placed in the acetabulum and a metal cap is placed over the head of the femur with limited removal of the femoral head and neck.

In some cases, the hip prosthesis may wear out or loosen. If loosening is painful, a second surgery, such as a revision or conversion may be necessary. In this procedure some or all of the components of the original replacement prosthesis are removed and replaced with new ones.

Hemiarthroplasty or partial hip replacement involves the reconstruction of the femoral head but not the acetabulum. This procedure is indicated for select traumatic events, guidelines for which fall outside of the scope of this document.

POLICY HISTORY

Date	Summary
May June-2022	<p><u>Deleted:</u></p> <ul style="list-style-type: none"> • <u>Documented risk and benefit discussion requirement- (THA)</u> • <u>“Efforts have been made to ensure that the patient is optimally informed and prepared for surgery” (general requirements)</u> <p><u>Revised:</u></p> <ul style="list-style-type: none"> • <u>Individual is medically stable and <i>optimized for surgery</i></u> • <u>3 months to 12 weeks throughout</u> • <u>“patient” to “individual” where appropriate</u>
June 2021	<ul style="list-style-type: none"> • Clarification of required X-ray findings: “X-rays described only as showing “severe”, “advanced” or “end-stage” arthritis require more definitive descriptions” • Added statement: Weightbearing X-rays are not required (Bessa, 2020). • Added: NOTE: MRI should not be the primary radiographic test used to determine the presence or severity of arthritic changes in the joint. • Revised requirements for revision arthroplasty. Inflammatory markers are not required if revision is for obvious hardware failure.
October 2020	<ul style="list-style-type: none"> • Added: Efforts have been made to ensure that the patient is optimally informed and prepared for surgery • Added: except in the case of malignancy • Removed: Metal allergy (dependent upon implant choice) (redundant)

	<ul style="list-style-type: none"> • Removed: Chronic renal insufficiency (due to metal ions circulating and potential renal toxicity) • Removed: Female of child-bearing age (due to metal ions circulating in blood with potential risk to fetus) (NOTE: This only applies to metal on metal replacements) (USFDA, 2018) • Reordered absolute contraindication ahead of relative • Added: Compromised soft tissue envelope • Added: Uncontrolled comorbidities (Clement, 2013) • Added: BMI > 40 (D'Apuzzo, 2014); without attempts at weight loss or discussion of increased risk conferred by BMI (consistent with TKA) • Added: or significant improvement in these markers and a clear statement by the treating surgeon that infection has been adequately treated ((to be consistent with TKA)) • Added: critical polyethylene wear
October 2019	<ul style="list-style-type: none"> • Added and updated references • Added new statement that if “bone on bone” arthritis is documented, conservative treatment requirements are not necessary for approval. • Decreased required documentation of symptoms from 6 months to 3 months • Added requirement specifically stating that risks/benefits/alternative discussion must be documented in office notes prior to surgical approval • Deleted Kellgren-Lawrence grading system • Moved metal-on-metal components in child-bearing age from absolute to relative contraindication • Removed Non covered services section
November 2018	<ul style="list-style-type: none"> • Total Hip Arthroplasty – Added: <i>Radiograph evaluation should include advanced osteoarthritis findings (joint space narrowing, subchondral sclerosis, subchondral cysts, osteophyte formation, etc.)</i> • Absolute Contraindications - Added ‘corticosteroid’ to specify ‘injection’; Added sentence “<i>If a local or remote infection is documented in the patient’s history, additional documentation showing the previous infection is resolved must be provided</i>” • Hip Resurfacing Arthroplasty - Added Absolute Contraindication: “Osteoporosis or poor bone quality may increase the risk of fixation failure or femoral neck fracture after hip resurfacing” • Total Hip Arthroplasty Revision/Conversion Arthroplasty: Changed ‘ruled out’ criteria from ‘synovial fluid

	<p>aspiration/biopsy (cell count and culture)’ to ‘ruled out by normal inflammatory markers (ESR and CRP)’; Added content: ‘If these inflammatory markers are elevated, further evaluation is required, including an aspiration with synovial fluid WBC count, gram stain and cultures, or an intraoperative frozen biopsy’ – Modified to match total knee guideline</p>
--	--

REFERENCES

~~Abbott JH, Robertson MC, Chapple C, et al. Manual therapy, exercise therapy, or both, in addition to usual care, for osteoarthritis of the hip or knee: A randomized controlled trial. 1: Clinical effectiveness. *Osteoarthritis Cartilage*. 2013; 1(4):525-534.~~

~~American Academy of Orthopaedic Surgeons (AAOS). Clinical Practice Guideline for Osteoarthritis of the Hip. April 11, 2017.~~

~~Bennell KL, Hinman RS. A review of the clinical evidence for exercise in osteoarthritis of the hip and knee. *J Sci Med Sport*. 2011; 14(1):4-9.~~

~~Bergh C, Fenstad AM, Furnes O, et al. Increased risk of revision in patients with non-traumatic femoral head necrosis: 11,589 cases compared to 416,217 cases with primary osteoarthritis in the NARA database, 1995-2011. *Acta Orthop*. 2014; 85(1):11-17.~~

~~Bessa FS, Williams BT, Polce EM, et al. No Differences in Hip Joint Space Measurements Between Weightbearing or Supine Anteroposterior Pelvic Radiographs. *Arthroscopy*. Vol 36, No.11, 2020, 2843-2848.~~

~~Bozic KJ, Lau E, Kurtz S, et al. Patient-related risk factors for periprosthetic joint infection and postoperative mortality following total hip arthroplasty in Medicare patients. *J Bone Joint Surg Am*. 2012; 94(9):794-800.~~

~~Bronson WH, Fewer M, Godlewski K, et al. The ethics of patient risk modification prior to elective joint replacement surgery. *J Bone Joint Surg Am*. 2014; 96(13):e113.~~

~~Brooks P, Strnad G. Hip resurfacing in patients under age 50: A large, US single surgeon series. *J Bone Joint Surg Am*. 2016; 98(Suppl 7):53-53.~~

~~Chambers AW, Lacy KW, Liow MH, et al. Multiple hip intra-articular steroid injections increase risk of periprosthetic joint infections compared with single injections. *J. Arthroplasty* 2017; 32(6): 1980-1983.~~

~~Clough EJ, Clough TM. Metal on metal hip resurfacing arthroplasty: Where are we now? *J Orthopedics*, 2021, Vol. 23: 123-127.~~

~~Della Valle C, Parvizi J, Bauer TW, et al. American Academy of Orthopaedic Surgeons. Diagnosis of periprosthetic joint infections of the hip and knee. *J Am Acad Orthop Surg*. 2010; 18:760-70.~~

~~Felson DT. Developments in the clinical understanding of osteoarthritis. *Arthritis Res Ther*. 2009; 11(1):203.~~

Fernandes, L, Hagen KB, Bijlsma JWI, et al. EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis. *Ann Rheum Dis*. 2013; 72(7):1125–1135.

Forlenza EM, Burnett RA, Korrapati A, et al. Preoperative Corticosteroid Injections Demonstrate a Temporal and Dose-Dependent Relationship with the Rate of Postoperative Infection Following Total Hip Arthroplasty. *J Arthroplasty*. 2021; 36(6):2033–2037.

Ghomrawi HMK, Schackman BR, Mushlin AI. Appropriateness criteria and elective procedures—total joint arthroplasty. *N Engl J Med*. 2012; 367(26):2467–2469.

Gierisch JM, Myers ER, Schmit KM, et al. Prioritization of patient-centered comparative effectiveness research for osteoarthritis. *Ann Intern Med*. 2014; 160(12):836–41.

Gossec L, Paternotte S, Maillefert JF, et al. The role of pain and functional impairment in the decision to recommend total joint replacement in hip and knee osteoarthritis: An international cross-sectional study of 1909 patients. Report of the OARSI-OMERACT Task Force on total joint replacement. *Osteoarthritis Cartilage*. 2011a; 19(2):147–154.

Gossec L, Paternotte S, Bingham 3rd CO, et al. OARSI/OMERACT initiative to define states of severity and indication for joint replacement in hip and knee osteoarthritis. An OMERACT 10 Special Interest Group. *J Rheumatol*. 2011b; 38(8):1765–1769.

Hawker GA, Badley EM, Borkhoff CM, et al. Which patients are most likely to benefit from total joint arthroplasty? *Arthritis Rheum*. 2013; 65(5):1243–1252.

Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. *Arthritis Care Res*. 2012; 64(4):465–474.

Inacio MC, Ake CF, Paxton EW, et al. Sex and risk of hip implant failure: Assessing total hip arthroplasty outcomes in the United States. *JAMA Intern Med*. 2013; 173(6):435–441.

Jain A, Stein BE, Skolasky RL, et al. Total joint arthroplasty in patients with rheumatoid arthritis: A United States experience from 1992 through 2005. *J Arthroplasty*. 2012 Jun; 27(6):881–8.

Jensen C, Roos EM, Kjaersgaard-Andersen P, et al. The effect of education and supervised exercise vs. education alone on the time to total hip replacement in patients with severe hip osteoarthritis. A randomized clinical trial protocol. *BMC Musculoskelet Disord*. 2013; 14(1):21.

Johnson AJ, Costa CR, Mont MA. Do we need gender-specific total joint arthroplasty? *Clin Orthop Relat Res*. 2011; 469(7):1852–1858.

Judge A, Arden NK, Price A, et al. Assessing patients for joint replacement: Can pre-operative Oxford hip and knee scores be used to predict patient satisfaction following joint replacement surgery and to guide patient selection? *J Bone Joint Surg Br.* 2011; 93(12):1660-1664.

Juhakoski R, Tenhonen S, Malmivaara A, et al. A pragmatic randomized controlled study of the effectiveness and cost consequences of exercise therapy in hip osteoarthritis. *Clin Rehabil.* 2011 Apr; 25(4):370-383.

Logishetty K, Muirhead-Allwood SK, Cobb JP. Hip resurfacing — what is its role in modern orthopaedics? *Bone Joint J*, 360 (1) (2020), pp. 4-9

Kim SH, Meehan JP, Lee MA. Surgical treatment of trochanteric and cervical hip fractures in the United States: 2000–2009. *J Arthroplasty.* 2013; 28(8):1386–90.

Klinger C, Dewar D, Sculco P, et al. Completing the picture: A comprehensive quantitative analysis of the femoral head and femoral neck blood supply. *Orthopaedic Proceedings.* 2016; 98(SUPP 7):111-111. https://online.boneandjoint.org.uk/doi/abs/10.1302/1358-992X.98BSUPP_7.ISTA2015-111.

Kosashvili Y, Drexler M, Backstein D, et al. Dislocation after the first and multiple revision total hip arthroplasty: Comparison between acetabulum-only, femur-only and both component revision hip arthroplasty. *Can J Surg.* 2014; 57(2):E15.

Kurtz SM, Ong KL, Lau E, et al. Impact of the economic downturn on total joint replacement demand in the United States: Updated projections to 2021. *J Bone Joint Surg.* 2014; 96(8):624-630.

Lee HD, Prashant K, Shon WY. Management of periprosthetic hip joint infection. *Hip Pelvis.* 2015; 27(2):63-71.

Matharu GS, McBryde CW, Revell MP, et al. Femoral neck fracture after Birmingham Hip Resurfacing arthroplasty: Prevalence, time to fracture, and outcome after revision. *J Arthroplasty.* 2013; 28(1):147-153.

Matharu GS, Berryman F, Judge A, et al. Blood metal ion thresholds to identify patients with metal-on-metal hip implants at risk of adverse reactions to metal debris: an external multicenter validation study of birmingham hip resurfacing and Corail-Pinnacle implants. *J Bone Joint Surg Am.* 2017 Sep 20; 99(18):1532-39.

Mota REM, Tarricone R, Ciani O, et al. Determinants of demand for total hip and knee arthroplasty: A systematic literature review. *BMCHSR.* 2012; 12(1):225.

Moya-Angeler J, Gianakos AL, Villa JC, et al. Current concepts on osteonecrosis of the femoral head. *World J Orthop.* 2015; 6(8):590-601.

~~Murphy DK, Randell T, Brennan KL, et al. Treatment and displacement affect the reoperation rate for femoral neck fracture. *Clin Orthop Relat Res*. 2013; 471(8):2691-2702.~~

~~Ng VY, Lustenberger D, Hoang K, et al. Preoperative risk stratification and risk reduction for total joint reconstruction AAOS exhibit selection. *J Bone Joint Surg*. 2013; 95(4):e19-1.~~

~~Nieuwenhuijse MJ, Nelissen RG, Schoones JW, et al. Appraisal of evidence base for introduction of new implants in hip and knee replacement: A systematic review of five widely used device technologies. *BMJ*. 2014; 349:g5133.~~

~~Nunley RM, Della Valle CJ, Barrack RL. Is patient selection important for hip resurfacing? *Clin Orthop Relat Res*. 2008; 467(1):56-65.~~

~~Ollivere B, Darrah C, Barker T, et al. Early clinical failure of the Birmingham metal-on-metal hip resurfacing is associated with metallosis and soft tissue necrosis. *J Bone Joint Surg Br*. 2009; 91(8):1025-1030.~~

~~Ollivier M, Parratte S, Le Corroller T, et al. Anatomy of the proximal femur at the time of total hip arthroplasty is a matter of morphotype and etiology but not gender. *Surg Radiol Anat*. 2015; 37(4):377-384.~~

~~Park CH, Lee YK, Koo KH. Lower urinary tract infection and periprosthetic joint infection after elective primary total hip arthroplasty. *Hip Pelvis*. 2017; 29(1):30-34.~~

~~Parvizi J, Gehrke T, Chen AF. Proceedings of the international consensus on periprosthetic joint infection. *Bone Joint J*. 2013; 95:1450-1452.~~

~~Parvizi, J, Tan TL, Goswami K, et al. The 2018 Definition of Periprosthetic Hip and Knee Infection: An Evidence-Based and Validated Criteria. *J Arthroplasty* 2018 vol 33(5); 1309-1314.~~

~~Pisters MF, Veenhof C, Schellevis FG, et al. Long-term effectiveness of exercise therapy in patients with osteoarthritis of the hip or knee: A randomized controlled trial comparing two different physical therapy interventions. *Osteoarthritis Cartilage*. 2010; 18(8):1019-1026.~~

~~Prokopetz JJZ, Losina E, Bliss RL, et al. Risk factors for revision of primary total hip arthroplasty: A systematic review. *BMC Musculoskelet Disord*. 2012; 13(1):251.~~

~~Ravi B, Escott BG, Wasserstein D, et al. Intraarticular hip injection and early revision surgery following total hip arthroplasty: A retrospective cohort study. *Arthritis Rheumatol*. 2015; 67(1):162-168.~~

~~Schairer WW, Nwachukwu BU, Mayman DJ, et al. Preoperative hip injections increase the rate of periprosthetic infection after total hip arthroplasty. *J Arthroplasty*. 2016; 9 Suppl:166-169.~~

~~Sershon R, Balkissoon R, Valle CJ. Current indications for hip resurfacing arthroplasty in 2016. *Curr Rev Musculoskelet Med*. 2016; 9(1):84-92.~~

~~Shears E, McBryde CW, O'Hara JN, et al. Outcome of Revision of metal on hip resurfacing. *J Bone Joint Surg Br.* 2011; 93(SUPP IV):548-548.~~

~~Stambough JB, Curtin BM, Odum SM, et al. Does change in ESR and CRP guide the timing of two-stage arthroplasty reimplantation? *Clin Orthop Relat Res.* 2019; 477:364-371. doi: 10.1097/01.blo.0000533618.31937.45.~~

~~Stephens BF, Murphy GA, Mihalko WM. The effects of nutritional deficiencies, smoking, and systemic disease on orthopaedic outcomes. *J Bone Joint Surg.* 2013; 95(23):2152-2157.~~

~~Taheriazam A, Mohseni G, Esmailieh AA, et al. Bilateral total hip arthroplasty: One-stage versus two-stage procedure. *Hip Int.* 2019; 29(2):141-146.~~

~~United States Food and Drug Administration (US FDA).
<https://www.fda.gov/medicaldevices/productsandmedicalprocedures/implantsandprosthetics/metalonmetalhipimplants/ucm241667.htm>.~~

~~Werner BC, Cancienne JM, Browne JA. The timing of total hip arthroplasty after intraarticular hip injection affects postoperative infection risk. *J Arthroplasty.* 2016; 31(4):820-823.~~

~~Wetters NG, Murray TG, Moric M, et al. Risk factors for dislocation after revision total hip arthroplasty. *Clin Orthop Relat Res.* 2013; 471(2):410-416.~~

~~**Reviewed / Approved by NIA Clinical Guideline Committee**~~

~~GENERAL INFORMATION~~

~~It is an expectation that all patients receive care/services from a licensed clinician. All appropriate supporting documentation, including recent pertinent office visit notes, laboratory data, and results of any special testing must be provided. If applicable: All prior relevant imaging results and the reason that alternative imaging cannot be performed must be included in the documentation submitted.~~

Disclaimer: Magellan Healthcare service authorization policies do not constitute medical advice and are not intended to govern or otherwise influence the practice of medicine. These policies are not meant to supplant your normal procedures, evaluation, diagnosis, treatment and/or care plans for your patients. Your professional judgement must be exercised and followed in all respects with regard to the treatment and care of your patients. These policies apply to all Magellan Healthcare subsidiaries including, but not limited to, National Imaging Associates ("Magellan"). The policies constitute only the reimbursement and coverage guidelines of Magellan. Coverage for services varies for individual members in accordance with the terms and conditions of applicable Certificates of Coverage, Summary Plan Descriptions, or contracts with governing regulatory agencies. Magellan reserves the right to review and update the guidelines at its sole discretion. Notice of such changes, if necessary, shall be provided in accordance with the terms and conditions of provider agreements and any applicable laws or regulations.

1. Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. *Arthritis Care Res (Hoboken)*. Apr 2012;64(4):465-74. doi:10.1002/acr.21596
2. Jain A, Stein BE, Skolasky RL, Jones LC, Hungerford MW. Total joint arthroplasty in patients with rheumatoid arthritis: a United States experience from 1992 through 2005. *J Arthroplasty*. Jun 2012;27(6):881-8. doi:10.1016/j.arth.2011.12.027
3. Kim SH, Meehan JP, Lee MA. Surgical treatment of trochanteric and cervical hip fractures in the United States: 2000-2009. *J Arthroplasty*. Sep 2013;28(8):1386-90. doi:10.1016/j.arth.2012.09.007
4. Murphy DK, Randell T, Brennan KL, Probe RA, Brennan ML. Treatment and displacement affect the reoperation rate for femoral neck fracture. *Clin Orthop Relat Res*. Aug 2013;471(8):2691-702. doi:10.1007/s11999-013-3020-9
5. Moya-Angeler J, Gianakos AL, Villa JC, Ni A, Lane JM. Current concepts on osteonecrosis of the femoral head. *World J Orthop*. Sep 18 2015;6(8):590-601. doi:10.5312/wjo.v6.i8.590
6. Gossec L, Paternotte S, Maillefert JF, et al. The role of pain and functional impairment in the decision to recommend total joint replacement in hip and knee osteoarthritis: an international cross-sectional study of 1909 patients. Report of the OARSI-OMERACT Task Force on total joint replacement. *Osteoarthritis Cartilage*. Feb 2011;19(2):147-54. doi:10.1016/j.joca.2010.10.025

7. Gossec L, Paternotte S, Bingham CO, 3rd, et al. OARSI/OMERACT initiative to define states of severity and indication for joint replacement in hip and knee osteoarthritis. An OMERACT 10 Special Interest Group. *J Rheumatol*. Aug 2011;38(8):1765-9. doi:10.3899/jrheum.110403
8. American Academy of Orthopaedic Surgeons (AAOS). Management of Osteoarthritis of the Hip Evidence-Based Clinical Practice Guideline. American Academy of Orthopaedic Surgeons. Updated March 13, 2017. Accessed January 24, 2022.
https://www.aaos.org/globalassets/quality-and-practice-resources/osteoarthritis-of-the-hip/oa-hip-cpg_6-11-19.pdf
9. Abbott JH, Robertson MC, Chapple C, et al. Manual therapy, exercise therapy, or both, in addition to usual care, for osteoarthritis of the hip or knee: a randomized controlled trial. 1: clinical effectiveness. *Osteoarthritis Cartilage*. Apr 2013;21(4):525-34. doi:10.1016/j.joca.2012.12.014
10. Juhakoski R, Tenhonen S, Malmivaara A, Kiviniemi V, Anttonen T, Arokoski JP. A pragmatic randomized controlled study of the effectiveness and cost consequences of exercise therapy in hip osteoarthritis. *Clin Rehabil*. Apr 2011;25(4):370-83. doi:10.1177/0269215510388313
11. Bessa FS, Williams BT, Polce EM, et al. No Differences in Hip Joint Space Measurements Between Weightbearing or Supine Anteroposterior Pelvic Radiographs. *Arthroscopy*. Nov 2020;36(11):2843-2848. doi:10.1016/j.arthro.2020.07.009
12. Forlenza EM, Burnett RA, Korrapati AB, Yang J, Forsythe B, Della Valle CJ. Preoperative Corticosteroid Injections Demonstrate a Temporal and Dose-Dependent Relationship with the Rate of Postoperative Infection Following Total Hip Arthroplasty. *J Arthroplasty*. Jun 2021;36(6):2033-2037.e1. doi:10.1016/j.arth.2021.01.076
13. Schairer WW, Nwachukwu BU, Mayman DJ, Lyman S, Jerabek SA. Preoperative Hip Injections Increase the Rate of Periprosthetic Infection After Total Hip Arthroplasty. *J Arthroplasty*. Sep 2016;31(9 Suppl):166-169.e1. doi:10.1016/j.arth.2016.04.008
14. Werner BC, Cancienne JM, Browne JA. The Timing of Total Hip Arthroplasty After Intraarticular Hip Injection Affects Postoperative Infection Risk. *J Arthroplasty*. Apr 2016;31(4):820-3. doi:10.1016/j.arth.2015.08.032
15. D'Apuzzo MR, Novicoff WM, Browne JA. The John Insall Award: Morbid obesity independently impacts complications, mortality, and resource use after TKA. *Clin Orthop Relat Res*. Jan 2015;473(1):57-63. doi:10.1007/s11999-014-3668-9
16. Clement N. Patient factors that influence the outcome of total knee replacement: a critical review of the literature. *OA Orthopaedics*. 2013 Aug 01 2013;1(2):11.
17. Sershon R, Balkissoon R, Valle CJ. Current indications for hip resurfacing arthroplasty in 2016. *Curr Rev Musculoskelet Med*. Mar 2016;9(1):84-92. doi:10.1007/s12178-016-9324-0
18. Nunley RM, Della Valle CJ, Barrack RL. Is patient selection important for hip resurfacing? *Clin Orthop Relat Res*. Jan 2009;467(1):56-65. doi:10.1007/s11999-008-0558-z
19. Clough EJ, Clough TM. Metal on metal hip resurfacing arthroplasty: Where are we now? *J Orthop*. Jan-Feb 2021;23:123-127. doi:10.1016/j.jor.2020.12.036
20. Matharu GS, Berryman F, Judge A, et al. Blood Metal Ion Thresholds to Identify Patients with Metal-on-Metal Hip Implants at Risk of Adverse Reactions to Metal Debris: An External Multicenter Validation Study of Birmingham Hip Resurfacing and Corail-Pinnacle Implants. *J Bone Joint Surg Am*. Sep 20 2017;99(18):1532-1539. doi:10.2106/jbjs.16.01568

21. Information for Orthopaedic Surgeons: General Recommendations for Orthopaedic Surgeons BEFORE Metal-on-Metal Hip Resurfacing Surgery. U.S. Food & Drug Administration (FDA). Updated March 15, 2019. Accessed January 24, 2022. <https://www.fda.gov/medical-devices/metal-metal-hip-implants/information-orthopaedic-surgeons>
22. Della Valle C, Parvizi J, Bauer TW, et al. Diagnosis of periprosthetic joint infections of the hip and knee. *J Am Acad Orthop Surg*. Dec 2010;18(12):760-70. doi:10.5435/00124635-201012000-00006
23. Ting NT, Della Valle CJ. Diagnosis of Periprosthetic Joint Infection-An Algorithm-Based Approach. *J Arthroplasty*. Jul 2017;32(7):2047-2050. doi:10.1016/j.arth.2017.02.070
24. Lee HD, Prashant K, Shon WY. Management of Periprosthetic Hip Joint Infection. *Hip Pelvis*. Jun 2015;27(2):63-71. doi:10.5371/hp.2015.27.2.63
25. Lee AJ, Armour P, Thind D, Coates MH, Kang AC. The prevalence of acetabular labral tears and associated pathology in a young asymptomatic population. *Bone Joint J*. May 2015;97-b(5):623-7. doi:10.1302/0301-620x.97b5.35166
26. Parvizi J, Gehrke T, Chen AF. Proceedings of the International Consensus on Periprosthetic Joint Infection. *Bone Joint J*. Nov 2013;95-b(11):1450-2. doi:10.1302/0301-620x.95b11.33135
27. Parvizi J, Tan TL, Goswami K, et al. The 2018 Definition of Periprosthetic Hip and Knee Infection: An Evidence-Based and Validated Criteria. *J Arthroplasty*. May 2018;33(5):1309-1314.e2. doi:10.1016/j.arth.2018.02.078
28. Parvizi J, Della Valle CJ. AAOS Clinical Practice Guideline: diagnosis and treatment of periprosthetic joint infections of the hip and knee. *J Am Acad Orthop Surg*. Dec 2010;18(12):771-2. doi:10.5435/00124635-201012000-00007

ADDITIONAL RESOURCES

1. Bennell KL, Hinman RS. A review of the clinical evidence for exercise in osteoarthritis of the hip and knee. *J Sci Med Sport*. Jan 2011;14(1):4-9. doi:10.1016/j.jsams.2010.08.002
2. Bergh C, Fenstad AM, Furnes O, et al. Increased risk of revision in patients with non-traumatic femoral head necrosis. *Acta Orthop*. Feb 2014;85(1):11-7. doi:10.3109/17453674.2013.874927
3. Bozic KJ, Lau E, Kurtz S, et al. Patient-related risk factors for periprosthetic joint infection and postoperative mortality following total hip arthroplasty in Medicare patients. *J Bone Joint Surg Am*. May 2 2012;94(9):794-800. doi:10.2106/jbjs.K.00072
4. Bronson WH, Fewer M, Godlewski K, et al. The Ethics of Patient Risk Modification Prior to Elective Joint Replacement Surgery. *J Bone Joint Surg Am*. Jul 2 2014;96(13):e113. doi:10.2106/jbjs.N.00072
5. Brooks PJ. Hip resurfacing: a large, US single-surgeon series. *Bone Joint J*. Jan 2016;98-b(1 Suppl A):10-3. doi:10.1302/0301-620x.98b1.36360
6. Chambers AW, Lacy KW, Liow MHL, Manalo JPM, Freiberg AA, Kwon YM. Multiple Hip Intra-Articular Steroid Injections Increase Risk of Periprosthetic Joint Infection Compared With Single Injections. *J Arthroplasty*. Jun 2017;32(6):1980-1983. doi:10.1016/j.arth.2017.01.030
7. Felson DT. Developments in the clinical understanding of osteoarthritis. *Arthritis Res Ther*. 2009;11(1):203. doi:10.1186/ar2531

8. [Fernandes L, Hagen KB, Bijlsma JW, et al. EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis. *Ann Rheum Dis*. Jul 2013;72\(7\):1125-35. doi:10.1136/annrheumdis-2012-202745](#)
9. [Ghomrawi HM, Schackman BR, Mushlin AI. Appropriateness criteria and elective procedures-total joint arthroplasty. *N Engl J Med*. Dec 27 2012;367\(26\):2467-9. doi:10.1056/NEJMp1209998](#)
10. [Gierisch JM, Myers ER, Schmit KM, et al. Prioritization of patient-centered comparative effectiveness research for osteoarthritis. *Ann Intern Med*. Jun 17 2014;160\(12\):836-41. doi:10.7326/m14-0318](#)
11. [Hawker GA, Badley EM, Borkhoff CM, et al. Which patients are most likely to benefit from total joint arthroplasty? *Arthritis Rheum*. May 2013;65\(5\):1243-52. doi:10.1002/art.37901](#)
12. [Inacio MC, Ake CF, Paxton EW, et al. Sex and risk of hip implant failure: assessing total hip arthroplasty outcomes in the United States. *JAMA Intern Med*. Mar 25 2013;173\(6\):435-41. doi:10.1001/jamainternmed.2013.3271](#)
13. [Jensen C, Roos EM, Kjærsgaard-Andersen P, Overgaard S. The effect of education and supervised exercise vs. education alone on the time to total hip replacement in patients with severe hip osteoarthritis. A randomized clinical trial protocol. *BMC Musculoskelet Disord*. Jan 14 2013;14:21. doi:10.1186/1471-2474-14-21](#)
14. [Johnson AJ, Costa CR, Mont MA. Do we need gender-specific total joint arthroplasty? *Clin Orthop Relat Res*. Jul 2011;469\(7\):1852-8. doi:10.1007/s11999-011-1769-2](#)
15. [Judge A, Arden NK, Price A, et al. Assessing patients for joint replacement: can pre-operative Oxford hip and knee scores be used to predict patient satisfaction following joint replacement surgery and to guide patient selection? *J Bone Joint Surg Br*. Dec 2011;93\(12\):1660-4. doi:10.1302/0301-620x.93b12.27046](#)
16. [Logishetty K, Muirhead-Allwood SK, Cobb JP. Hip resurfacing—what is its role in modern orthopaedics? *Bone & Joint* 360. 2020;9\(1\):4-9.](#)
17. [Klinger C, Dewar D, Sculco P, et al. Completing the picture: a comprehensive quantitative analysis of the femoral head and femoral neck blood supply. *Orthopaedic Proceedings*. 2016;98-B\(SUPP 7\):111-111. doi:10.1302/1358-992x.98bsupp 7.Ista2015-111](#)
18. [Kosashvili Y, Drexler M, Backstein D, et al. Dislocation after the first and multiple revision total hip arthroplasty: comparison between acetabulum-only, femur-only and both component revision hip arthroplasty. *Can J Surg*. Apr 2014;57\(2\):E15-8. doi:10.1503/cjs.000913](#)
19. [Kurtz SM, Ong KL, Lau E, Bozic KJ. Impact of the economic downturn on total joint replacement demand in the United States: updated projections to 2021. *J Bone Joint Surg Am*. Apr 16 2014;96\(8\):624-30. doi:10.2106/jbjs.M.00285](#)
20. [Matharu GS, McBryde CW, Revell MP, Pynsent PB. Femoral neck fracture after Birmingham Hip Resurfacing Arthroplasty: prevalence, time to fracture, and outcome after revision. *J Arthroplasty*. Jan 2013;28\(1\):147-53. doi:10.1016/j.arth.2012.04.035](#)
21. [Mota RE, Tarricone R, Ciani O, Bridges JF, Drummond M. Determinants of demand for total hip and knee arthroplasty: a systematic literature review. *BMC Health Serv Res*. Jul 30 2012;12:225. doi:10.1186/1472-6963-12-225](#)
22. [Ng VY, Lustenberger D, Hoang K, et al. Preoperative risk stratification and risk reduction for total joint reconstruction: AAOS exhibit selection. *J Bone Joint Surg Am*. Feb 20 2013;95\(4\):e191-15. doi:10.2106/jbjs.L.00603](#)

23. Nieuwenhuijse MJ, Nelissen RG, Schoones JW, Sedrakyan A. Appraisal of evidence base for introduction of new implants in hip and knee replacement: a systematic review of five widely used device technologies. *BMJ*. Sep 9 2014;349:g5133. doi:10.1136/bmj.g5133
24. Olliviere B, Darrah C, Barker T, Nolan J, Porteous MJ. Early clinical failure of the Birmingham metal-on-metal hip resurfacing is associated with metallosis and soft-tissue necrosis. *J Bone Joint Surg Br*. Aug 2009;91(8):1025-30. doi:10.1302/0301-620x.91b8.21701
25. Ollivier M, Parratte S, Le Corroller T, Reggiori A, Champsaur P, Argenson JN. Anatomy of the proximal femur at the time of total hip arthroplasty is a matter of morphotype and etiology but not gender. *Surg Radiol Anat*. May 2015;37(4):377-84. doi:10.1007/s00276-014-1368-5
26. Park CH, Lee YK, Koo KH. Lower Urinary Tract Infection and Periprosthetic Joint Infection after Elective Primary Total Hip Arthroplasty. *Hip Pelvis*. Mar 2017;29(1):30-34. doi:10.5371/hp.2017.29.1.30
27. Prokopetz JJ, Losina E, Bliss RL, Wright J, Baron JA, Katz JN. Risk factors for revision of primary total hip arthroplasty: a systematic review. *BMC Musculoskelet Disord*. Dec 15 2012;13:251. doi:10.1186/1471-2474-13-251
28. Ravi B, Escott BG, Wasserstein D, et al. Intraarticular hip injection and early revision surgery following total hip arthroplasty: a retrospective cohort study. *Arthritis Rheumatol*. Jan 2015;67(1):162-8. doi:10.1002/art.38886
29. Shears E, McBryde C, O'Hara J, Pynsent P. Outcome of revision of metal on metal hip resurfacing. *Orthopaedic Proceedings*. 2011;93-B(SUPP IV):548-548. doi:10.1302/0301-620X.93BSUPP IV.0930548d
30. Stambough JB, Curtin BM, Odum SM, Cross MB, Martin JR, Fehring TK. Does Change in ESR and CRP Guide the Timing of Two-stage Arthroplasty Reimplantation? *Clin Orthop Relat Res*. Feb 2019;477(2):364-371. doi:10.1097/01.blo.0000533618.31937.45
31. Stephens BF, Murphy A, Mihalko WM. The effects of nutritional deficiencies, smoking, and systemic disease on orthopaedic outcomes. *J Bone Joint Surg Am*. Dec 4 2013;95(23):2152-7. doi:10.2106/00004623-201312040-00010
32. Taheriazam A, Mohseni G, Esmailiejah AA, Safdari F, Abrishamkarzadeh H. Bilateral total hip arthroplasty: one-stage versus two-stage procedure. *Hip Int*. Mar 2019;29(2):141-146. doi:10.1177/1120700018773427
33. Wetters NG, Murray TG, Moric M, Sporer SM, Paprosky WG, Della Valle CJ. Risk factors for dislocation after revision total hip arthroplasty. *Clin Orthop Relat Res*. Feb 2013;471(2):410-6. doi:10.1007/s11999-012-2561-7

Reviewed / Approved by NIA Clinical Guideline Committee

GENERAL INFORMATION

It is an expectation that all patients receive care/services from a licensed clinician. All appropriate supporting documentation, including recent pertinent office visit notes, laboratory data, and results of any special testing must be provided. If applicable: All prior relevant imaging results and the reason that alternative imaging cannot be performed must be included in the documentation submitted.

Disclaimer: Magellan Healthcare service authorization policies do not constitute medical advice and are not intended to govern or otherwise influence the practice of medicine. These policies are not meant to supplant your normal procedures, evaluation, diagnosis, treatment and/or care plans for your patients. Your professional judgement must be exercised and followed in all respects with regard to the treatment and care of your patients. These policies apply to all Magellan Healthcare subsidiaries including, but not limited to, National Imaging Associates (“Magellan”). The policies constitute only the reimbursement and coverage guidelines of Magellan. Coverage for services varies for individual members in accordance with the terms and conditions of applicable Certificates of Coverage, Summary Plan Descriptions, or contracts with governing regulatory agencies. Magellan reserves the right to review and update the guidelines at its sole discretion. Notice of such changes, if necessary, shall be provided in accordance with the terms and conditions of provider agreements and any applicable laws or regulations.